Abstract Parainfluenza virus 3 (PIV3) remains to be a global burden infants, the elderly, and immunocompromised individuals. With no approved therapeutics or vaccines, PIV3 continues cause large portion of lower respiratory illness hospitalizations in young children. Similar other paramyxoviruses, utilizes two structural proteins, fusion (F) protein hemagglutinin-neuraminidase (HN) protein, for...